Table 2.
Demographic and clinical characteristics of the 143 hand OA patients in randomized controlled trial 1 and 2 according to clinically significant improvement
| Response (−) (n = 89) |
Response (+) (n = 54) |
P-value | |
|---|---|---|---|
| Age, years | 58.1 ± 7.5 | 60 ± 8.2 | 0.164 |
| Female | 81 (91.0) | 53 (98.1) | 0.153 |
| Weight, kg | 59.1 ± 8.3 | 59.9 ± 8.3 | 0.606 |
| Height, cm | 157.3 ± 5.9 | 155.8 ± 6.2 | 0.150 |
| BMI, kg/m2 | 23.9 ± 2.7 | 24.7 ± 3.1 | 0.105 |
| OA duration, month | 3.2 ± 4 | 3.5 ± 5.1 | 0.657 |
| AUSCAN Pain | 43.6 ± 21.6 | 55.7 ± 19.7 | 0.001 |
| AUSCAN Stiffness | 57.5 ± 24.5 | 68.2 ± 20.5 | 0.008 |
| AUSCAN Function | 41.7 ± 23.2 | 49.1 ± 26.6 | 0.083 |
| Patient GA | 51.1 ± 16 | 55.6 ± 19.9 | 0.158 |
| Physician GA | 40.1 ± 11.3 | 43.7 ± 13.6 | 0.084 |
| Tender JC | 5.8 ± 4.7 | 6.5 ± 5.7 | 0.426 |
| Swollen JC | 0.8 ± 2.4 | 0.5 ± 1.5 | 0.328 |
| Enlarged JC a | 5.1 ± 2.7 | 5.4 ± 2.2 | 0.622 |
| Deformity JC a | 2 ± 1.6 | 1.9 ± 1.9 | 0.658 |
| ESR | 0.17 ± 0.52 | 0.09 ± 0.13 | 0.291 |
| CRP | 13.4 ± 10.4 | 14.5 ± 9.6 | 0.533 |
| Prior treatment | |||
| Tramadol-AAP a | 3 (4.6) | 7 (18.9) | 0.034 |
| Tramadol a | 1 (1.5) | 0 (0) | 1.000 |
| NSAIDs a | 22 (33.8) | 14 (37.8) | 0.685 |
| Diacerin a | 2 (3.1) | 1 (2.7) | 1.000 |
| Glucosamine a | 9 (13.8) | 4 (10.8) | 0.765 |
| Others a | 1 (1.5) | 2 (5.4) | 0.297 |
Data are presented as the mean (SD) or n (%). P values were generated by using an independent t-test (continuous variables) or the Chi-squared test (categorical variables). a Data were not available in the placebo group of RCT 2. AUSCAN Australian/Canadian Osteoarthritis Hand Index, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, NSAID Non-steroidal anti-inflammatory drug, OA Osteoarthritis. Joints according to ACR OA classification criteria were evaluated.